Pegcetacoplan (Empaveli) is a complement C3 inhibitor that has been approved in 2021 as a medication to treat paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.

纯度：≥98%

CAS：2019171-69-6